Status:
UNKNOWN
Early Conversion of Dasatinib in CML-CP Patients
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
Validity and Safety
Eligibility:
All Genders
18-65 years
Brief Summary
Chronic myeloid leukemia (CML) is a malignant disease of acquired hematopoietic stem cells. The BCR-ABL fusion gene is the pathogenic basis of CML. Tyrosine kinase inhibitors (TKIs) are targeted drugs...
Eligibility Criteria
Inclusion
- 18-65 years old； 2.CML-CP,and Imatinib treatment longest for 6 months ； 3.Q-pcr monitoring of BCR/ABLIS failed to achieve the best therapeutic effect（BCR/ABLIS\>10.00% in 3m or BCR/ABLIS\>1.00% in 6m）； 4.No previous history of malignant tumor; 5.Informed consent of the patient or his legal representative
Exclusion
- History of CML-CP or CML-AP;
- Resistant to dasatinib,or treatment with imatinib more than 6 months;
- Received allogeneic hematopoietic stem cell transplantation,or immunotherapy;
- woman who is pregnant or nursing
- Combined with other serious organic diseases, serious arrhythmia, pulmonary hypertension, cardiomyopathy, serious autoimmune diseases.
Key Trial Info
Start Date :
October 22 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04136015
Start Date
October 22 2019
End Date
December 31 2021
Last Update
December 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NanfangH
Guangzhou, Guangdong, China, 510515